@article{98145775448e464089b4dec8b6da8213,
title = "Plasma estrogen concentrations after oral and vaginal estrogen administration in women with atrophic vaginitis",
abstract = "In this open-label, randomized, multiple-dose, two-treatment crossover study, 24 postmenopausal women with moderate to severe atrophic vaginitis received 0.3 mg conjugated estrogens daily for 14 days: 7 days orally (0.3 mg tablet) and 7 days vaginally (0.5 g cream). Steady-state plasma concentrations of E2 and estrone were one-third lower after vaginal versus oral administration of conjugated estrogens.",
keywords = "absorption, Conjugated estrogens, ET, pharmacokinetics, vaginal cream",
author = "Dorr, {Mary Beth} and Nelson, {Anita L.} and Mayer, {Philip R.} and Ranganath, {Radhika P.} and Norris, {Paul M.} and Helzner, {Eileen C.} and Preston, {Richard A.}",
note = "Funding Information: M.B.D., P.M., R.R., and E.H. were employees of Wyeth Research during the time the research was conducted. A.N. has received honoraria for participating in Wyeth's speaker's bureau, and her clinic has received research grants from Wyeth . The University of Miami Division of Clinical Pharmacology was awarded a clinical research grant by Wyeth to conduct this research study. P.N. has nothing to disclose. R.P. has nothing to disclose. Funding Information: Supported by Wyeth Research . Premarin and Premarin Vaginal Cream are manufactured and marketed by Pfizer, formerly Wyeth. Medical writing support for this manuscript was provided by Irene Durham, Laini Dubach, and Bo Choi, Ph.D., and was funded by Wyeth . Copyright: Copyright 2011 Elsevier B.V., All rights reserved.",
year = "2010",
month = nov,
doi = "10.1016/j.fertnstert.2010.03.076",
language = "English (US)",
volume = "94",
pages = "2365--2368",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "6",
}